Lexeo Therapeutics, INC Schedule 13G passive stakes

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, reporting beneficial ownership of 4.1% and 1.0% respectively in Lexeo Therapeutics, Inc.

Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 5.3% of Lexeo Therapeutics, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and its affiliates have reported beneficial ownership of 9.99% of Lexeo Therapeutics, Inc. common stock, totaling 7,844,311 shares.

State Street Corporation has disclosed a beneficial ownership of 5.5% in Lexeo Therapeutics Inc. as of June 30, 2026.

Paradigm BioCapital Advisors and affiliates have reported an 8.3% beneficial ownership stake in Lexeo Therapeutics, Inc.

Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership of 9.69% in Lexeo Therapeutics, Inc. common stock as of March 31, 2026.

Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Aaron Cowen, has reported beneficial ownership of 7.7% of Lexeo Therapeutics, Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Lexeo Therapeutics Inc. following an internal realignment.

Balyasny Asset Management and its affiliates report a 9.89% beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 7,221,555 shares.

Frazier Life Sciences Public Fund and affiliated entities filed an amended Schedule 13G, disclosing beneficial ownership in Lexeo Therapeutics, Inc. as of December 31, 2025.

The Vanguard Group has reported a 5.33% beneficial ownership stake in Lexeo Therapeutics Inc., holding 3,894,310 shares of common stock.

Affinity Asset Advisors and Michael Cho have increased their beneficial ownership in Lexeo Therapeutics, Inc. to 7.1% of common stock.

BlackRock, Inc. has reported a 6.7% beneficial ownership stake in Lexeo Therapeutics, Inc., holding 4,885,814 shares of common stock.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in LEXEO Therapeutics, Inc., holding 7,291,434 shares of common stock.

Paradigm BioCapital Advisors LP and related entities have reported a 5.0% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.

Longitude Capital Partners IV, LLC and related entities have updated their beneficial ownership in Lexeo Therapeutics, Inc. to 3.8% of common stock.

Vestal Point Capital, LP and Ryan Wilder have disclosed a 7.5% beneficial ownership stake in Lexeo Therapeutics, Inc., including shares from warrants.

Janus Henderson Group plc, through its subsidiaries, reported an 11.3% beneficial ownership stake in LEXEO THERAPEUTICS, INC. as of September 30, 2025.

Balyasny Asset Management and its affiliates have reported a 9.99% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.

Millennium Management and related entities have disclosed a 3.2% passive beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.

RA Capital Management and its affiliates have reported a 6.9% beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 5,000,000 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.0% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a 9.6% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.

Vestal Point Capital, LP and Ryan Wilder have reported a 6.0% beneficial ownership stake in Lexeo Therapeutics, Inc.'s common stock.

Frazier Life Sciences and affiliated funds have filed an amended Schedule 13G, disclosing their beneficial ownership in Lexeo Therapeutics, Inc. common stock.

Janus Henderson Group plc and its affiliate report a combined 11.1% beneficial ownership in LEXEO Therapeutics, Inc. common stock.

Balyasny Asset Management and its affiliates have disclosed a 9.99% passive beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 8,345,651 shares.

Millennium Management and related entities have disclosed beneficial ownership of 5.3% of Lexeo Therapeutics, Inc. common stock.

Frazier Life Sciences and its affiliated funds have filed a Schedule 13G, revealing a collective beneficial ownership of up to 9.9% in Lexeo Therapeutics, Inc., primarily through direct shareholdings and exercisable warrants.

Affinity Healthcare Fund, LP and its advisor, Affinity Asset Advisors, LLC, have disclosed a 7.75% beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 4,252,005 shares of common stock.